Literature DB >> 21825239

Deep brain stimulation in benign tremulous parkinsonism.

Rodolfo Savica1, Joseph Y Matsumoto, Keith A Josephs, J Eric Ahlskog, Matt Stead, Kendall H Lee, Bryan T Klassen.   

Abstract

BACKGROUND: Benign tremulous parkinsonism (BTP) is characterized by prominent resting plus action tremor, mild parkinsonism with limited disability or progression apart from tremor, and a less-robust response to levodopa therapy. This disorder has an uncertain pathophysiologic relationship to idiopathic Parkinson disease. Deep brain stimulation (DBS) should be efficacious for this condition, but there is no previously published experience.
OBJECTIVES: To assess the clinical outcomes and surgical complications of patients with BTP who underwent DBS.
DESIGN: Retrospective case series.
SETTING: Tertiary care medical center. PATIENTS: Twelve men and 3 women with BTP who underwent DBS for levodopa-refractory tremor. MAIN OUTCOME MEASURES: Tremor status after DBS, preoperative vs postoperative scores on the Fahn-Tolosa-Marin tremor scale, and the presence of adverse events.
RESULTS: Of the 15 patients, 8 underwent unilateral thalamic nucleus ventralis intermedius (VIM), 4 bilateral VIM, and 3 bilateral subthalamic nucleus DBS. At last follow-up at a median of 4 years post-DBS, 7 patients were tremor free, 6 had only trace tremor, and 2 were definitely improved but with residual tremor. The median preoperative Fahn-Tolosa-Marin tremor scale score was 17 (range, 11-21); the tremor scale score at the last videotaped follow-up was 1 (range, 0-6). Median time between the 2 videotapes was 11.5 months (range, 3-14 months). No patients experienced adverse events after the surgical procedure.
CONCLUSIONS: These findings support the efficacy of DBS, with VIM and STN targets, in medically refractory BTP-related tremor. Further studies are needed to explore the long-term durability of response and to better compare the surgical targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21825239     DOI: 10.1001/archneurol.2011.160

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  7 in total

1.  Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial.

Authors:  Aaron E Bond; Binit B Shah; Diane S Huss; Robert F Dallapiazza; Amy Warren; Madaline B Harrison; Scott A Sperling; Xin-Qun Wang; Ryder Gwinn; Jennie Witt; Susie Ro; W Jeffrey Elias
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

2.  Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism.

Authors:  Takuya Konno; Owen A Ross; Robert E Wharen; Ryan J Uitti; Zbigniew K Wszolek
Journal:  Neurol Neurochir Pol       Date:  2016-06-24       Impact factor: 1.621

Review 3.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Comparison of VIM and STN DBS for Parkinsonian Resting and Postural/Action Tremor.

Authors:  Raminder Parihar; Ron Alterman; Efstathios Papavassiliou; Daniel Tarsy; Ludy C Shih
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-07-06

5.  Deep Brain Stimulation Target Selection in an Advanced Parkinson's Disease Patient with Significant Tremor and Comorbid Depression.

Authors:  Amar S Patel
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-04-11

6.  Comparison of Parkinson's Disease Patients' Characteristics by Indication for Deep Brain Stimulation: Men Are More Likely to Have DBS for Tremor.

Authors:  W Alex Dalrymple; Antonia Pusso; Scott A Sperling; Joseph L Flanigan; Diane S Huss; Madaline B Harrison; W Jeffrey Elias; Binit B Shah; Matthew J Barrett
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-09-17

Review 7.  Benign tremulous Parkinsonism: a unique entity or another facet of Parkinson's disease?

Authors:  Wissam Deeb; Wei Hu; Leonardo Almeida; Addie Patterson; Daniel Martinez-Ramirez; Aparna Wagle Shukla
Journal:  Transl Neurodegener       Date:  2016-05-20       Impact factor: 8.014

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.